--- title: "首次公開募股動態：Avalyn Pharma（AVLN）將擴大後的 IPO 定價為 18 美元——頂級——股票大漲" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/284818412.md" description: "Avalyn Pharma (AVLN) 將其增發的 1667 萬股 IPO 定價為 18.00 美元，籌集了 3.0006 億美元。該股票在納斯達克首日交易中飆升至 26.00 美元，漲幅達到 44.44%。該公司專注於稀有呼吸系統疾病的吸入治療，主要候選藥物 AP01 和 AP02 正在進行臨牀試驗。儘管 IPO 成功，Avalyn 仍報告了 8520 萬美元的淨虧損，且去年沒有收入" datetime: "2026-04-30T17:05:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284818412.md) - [en](https://longbridge.com/en/news/284818412.md) - [zh-HK](https://longbridge.com/zh-HK/news/284818412.md) --- # 首次公開募股動態：Avalyn Pharma（AVLN）將擴大後的 IPO 定價為 18 美元——頂級——股票大漲 **Avalyn Pharma (AVLN**), **a clinical biotech pioneering inhaled treatments for rare respiratory disorders, priced its upsized IPO of 16.67 million shares at** **$18.00 – the top of its $16.00-to-$18.00 price range – and raised $300.06 million on Wednesday night, April 29, 2026. Shares of Avalyn Pharma (AVLN**) **surged in their NASDAQ debut to open at $26.00 – up $8.00 from the IPO price for a 44.44 percent gain – at 12:23 p.m. EDT today – Thursday, April 30, 2026 – on volume of 813,133 shares. Avalyn Pharma’s stock kept climbing – trading at $27.45 at 12:54 p.m. EDT.** **Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities acted as the joint book-runners on Avalyn’s IPO.** **Avalyn Pharma, focused on pulmonary fibrosis, increased its IPO’s size yesterday to 16.67 million shares – up from 11.8 million shares originally – to raise $283.39 million, if priced at the $17.00 mid-point of its range.** **Avalyn Pharma (AVLN), based in Boston, is focused on developing inhaled treatments for progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF).** **In the prospectus, Avalyn Pharma (AVLN) said its leading drug candidate, AP01 , is an inhaled formulation of pirfenidone to treat progressive pulmonary fibrosis (PPF), and its other leading drug candidate, AP02, is an inhaled formulation of nintedanib to treat idiopathic pulmonary fibrosis, or IPF.** **AP01 is currently being evaluated in MIST, a global Phase 2b clinical trial for the treatment of PPF, according to the prospectus.** **AP02 is currently being evaluated in AURA, a global Phase 2 clinical trial for the treatment of IPF.** **“We are also advancing AP03 into a Phase 1 clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit,” Avalyn Therapeutics said in the prospectus.** **Avalyn Pharma (AVLN) is not profitable: The company reported a net loss of $85.2 million on no revenue for the 12 months that ended Dec. 31, 2025, according to financial statements in the prospectus.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### 相關股票 - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [TMED.US](https://longbridge.com/zh-HK/quote/TMED.US.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [MS.US](https://longbridge.com/zh-HK/quote/MS.US.md) - [JEF.US](https://longbridge.com/zh-HK/quote/JEF.US.md) - [EVR.US](https://longbridge.com/zh-HK/quote/EVR.US.md) - [NDAQ.US](https://longbridge.com/zh-HK/quote/NDAQ.US.md) - [MS-O.US](https://longbridge.com/zh-HK/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/zh-HK/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/zh-HK/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/zh-HK/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/zh-HK/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/zh-HK/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/zh-HK/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/zh-HK/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/zh-HK/quote/MS-K.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [Relay 藥物在治療罕見血管疾病方面顯示出早期的潛力](https://longbridge.com/zh-HK/news/287094432.md) - [Eton Pharmaceuticals 增加了一個 2026 年的新產品發佈，因為它獲得了 IMPAVIDO 在美國的銷售權](https://longbridge.com/zh-HK/news/287025596.md) - [拜瑪林製藥藥物在後期臨牀試驗中顯示兒童生長顯著增益](https://longbridge.com/zh-HK/news/287121584.md)